Drug Profile
Research programme: rheumatoid arthritis gene therapy - Boehringer Ingelheim/Valentis
Alternative Names: Rheumatoid arthritis research programme - Boehringer Ingelheim/ValentisLatest Information Update: 14 Jun 2001
Price :
$50
*
At a glance
- Originator Boehringer Ingelheim; Valentis
- Developer Valentis
- Class Antirheumatics; Gene therapies
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Rheumatoid arthritis
Most Recent Events
- 30 Nov 2000 Discontinued - Preclinical for Rheumatoid arthritis in USA (unspecified route)
- 24 Sep 1999 New profile
- 24 Sep 1999 Preclinical development for Rheumatoid arthritis in USA (Unknown route)